The latest announcement is out from Bicycle Therapeutics ( (BCYC) ).
Bicycle Therapeutics announced several key leadership changes and appointments on March 27, 2025, including the addition of Alessandro Riva, M.D., to the Board of Directors and the Scientific Committee, and the promotion of Eric Westin, M.D., to Chief Medical Officer. These changes, along with the retirement of Pierre Legault and Richard Kender from the Board, are part of the company’s strategy to strengthen its expertise in oncology and position itself as a leader in cancer drug development. The company also highlighted the transition of Santiago Arroyo, M.D., Ph.D., to a consulting role, ensuring continued strategic advice and support.
More about Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company focused on developing a new class of medicines known as Bicycle® molecules. These fully synthetic short peptides are designed with small molecule scaffolds to enhance target binding with high affinity and selectivity, making them promising candidates for drug development. The company is actively evaluating several Bicycle® Drug Conjugates and Bicycle Tumor-Targeted Immune Cell Agonists in clinical trials, and is also exploring the use of its technology for radiopharmaceutical applications and other diseases beyond oncology.
YTD Price Performance: -39.21%
Average Trading Volume: 326,147
Technical Sentiment Signal: Buy
Current Market Cap: $611.2M
For an in-depth examination of BCYC stock, go to TipRanks’ Stock Analysis page.